Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

113.85USD
3:56pm EST
Change (% chg)

$-0.30 (-0.26%)
Prev Close
$114.15
Open
$114.55
Day's High
$114.77
Day's Low
$113.83
Volume
1,282,026
Avg. Vol
2,354,708
52-wk High
$126.07
52-wk Low
$96.04

Select another date:

UPDATE 3-Actelion drug setback unlikely to derail J&J talks - analysts

* Shares pare losses after falling more than 1 pct (Releads, adds analyst reactions, updates shares)

MDL Watch: Sanofi Taxotere, Bair Hugger and J&J talc cases grow

New multidistrict litigation over claims that a Sanofi breast cancer drug causes permanent hair loss more than doubled in size over the past month, and plaintiffs are continuing to mount ovarian cancer claims involving Johnson & Johnson's talc products in federal court.

BRIEF-Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016

* Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing Source text: (http://bit.ly/2j9ZI8k) Further company coverage:

EU mergers and takeovers (Jan 18)

BRUSSELS, Jan 18 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

U.S. Supreme Court declines to hear J&J contact lens patent dispute

Johnson & Johnson will have to face a retrial of patent infringement claims over contact lens technology after the U.S. Supreme Court on Tuesday refused to review a lower court's decision overturning the company's win at an earlier trial.

11th Circuit asked to block former J&J executive's job with rival

Two Johnson & Johnson units have asked a U.S. appeals court to uphold a ruling that blocked a former longtime executive from taking a high-profile role at a rival medical device maker, saying her defection poses an imminent risk to the companies.

BRIEF-Orthocell announces collaboration with Johnson & Johnson

* Orthocell announces collaboration with Johnson & Johnson Innovation

J&J, Actelion approach Swiss takeover board over deal structure: paper

ZURICH Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.

J&J, Actelion approach Swiss takeover board over deal structure -paper

ZURICH, Jan 6 Johnson & Johnson and Actelion have asked Switzerland's takeover board about the viability of a complicated takeover deal the U.S. healthcare company is discussing with the Swiss biotech firm, newspaper Tages-Anzeiger reported on Friday, without saying how it got the information.

Judge halves $1 billion award in J&J hip implants case

A U.S. judge almost halved the award in a December jury verdict that ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to plaintiffs in six lawsuits who said they were injured by DePuy's Pinnacle hip implants.

Select another date: